Evidence map›Paper›PMID 39772133›Full record

ArticleViruses2024

Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic.

Alessandra Vergori, Nicola Gianotti, Alessandro Tavelli, Camilla Tincati, Andrea Giacomelli, Elena Matteini, Giuseppe Lapadula, Lucia Taramasso, Loredana Sarmati, Antonella D'Arminio Monforte and 4 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alessandra VergoriViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00143 Roma, Italy.ORCID 0000-0001-6944-0686
Nicola GianottiInfectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, 20133 Milano, Italy.ORCID 0000-0002-7182-5080
Alessandro TavelliIcona Foundation, 20133 Milan, Italy.
Camilla TincatiClinica di Malattie Infettive, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo-Presidio Ospedaliero San Paolo, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0002-3083-2962
Andrea GiacomelliDepartment of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0003-3685-4289
Elena MatteiniDipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, 00143 Roma, Italy.
Giuseppe LapadulaIRCCS Fondazione San Gerardo, Monza, Università di Milano Bicocca, 20133 Milano, Italy.ORCID 0000-0002-9976-8102
Lucia TaramassoInfectious Disease Clinic, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Policlinico San Martino Hospital, 16132 Genova, Italy.ORCID 0000-0002-6622-6358
Loredana SarmatiClinical Infectious Diseases, Department of System Medicine, Tor Vergata University, 00143 Roma, Italy.ORCID 0000-0003-1452-0333
Antonella D'Arminio MonforteIcona Foundation, 20133 Milan, Italy.ORCID 0000-0003-0073-1789
Andrea AntinoriViral Immunodeficiency Unit, National Institute for Infectious Diseases L. Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00143 Roma, Italy.ORCID 0000-0003-2121-4684
Alessandro Cozzi-LepriCentre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, Univesity College London, London WC1E 6BT, UK.ORCID 0000-0002-6339-919X
On Behalf Of The Icona Foundation Study
ICONA Foundation Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-HIV AgentsCOVID-19HIV InfectionsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCOVID-19 Drug TreatmentDrug Therapy, CombinationFemaleHumansItalyMaleMiddle AgedPandemicsProbabilitySARS-CoV-2Anti-HIV AgentsAnti-Retroviral Agents2DR3DRCOVID-19 lockdownHIV

Identifiers

PMID39772133
PMCPMC11680257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.